Israel Steiner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Israel Steiner has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Amos Panet
Department of Virology, The Hebrew University, Hadassah Medical School, Jerusalem, Israel
3 shared publications- Bettina Steiner-Birmanns
Department of Neurology, Shaare Zedek Medical Center, Jerusalem, Israel
3 shared publications Oren Cohen
Department of Neurology, Hadassah University Hospital, PO Box 12000, Ein Karem, Jerusalem 91120, Israel
3 shared publicationsEfrat Braun
Laboratory of Neurovirology, Department of Neurology, Hadassah University Hospital, PO Box 12000, Jerusalem 91120, Israel
2 shared publicationsI. Wirguin
Dept. of Neurology, Soroka Medical Center, Ben Gurion University, Faculty of Health Sciences, Beer Sheva, Israel
2 shared publicationsIftah Biran
Departments of Neurology1 and Dermatology,2 Hadassah University Hospital, and The Neurological Service, Bikur Cholim Hospital,3 Jerusalem, Israel
2 shared publications
Latest Publications
- 30 April 2008
- Published by Springer Nature in Journal of Neurology
- Vol. 255 (6) , 813-819
Increased severity over generations of Charcot-Marie-Tooth disease type 1A
Background Charcot-Marie-Tooth type 1A (CMT1A) is an autosomal dominant polyneuropathy due to a 1.5 Mb tandem duplication in chromosome 17p11.2, containing the PMP22 gene. This mutation is not modified during inheritance. Objectives We set forth to test the hypothesis that in a subgroup of CMT1A patients there is clinical anticipation, namely an increase in disease severity over generations. Methods Thirty-nine CMT1A mutation-positive patients in 16 families and 23 parent-offspring pairs were evaluated. This included 14 families with 2 generations and 2 families with 3 generations. Age of presentation was assessed by interviewing the patients and clinical severity was measured using the CMT neuropathy score (CMTNS). Results In 21/23 parent-child pairs and 14/16 families, there was an earlier age of presentation in children of genetically affected parents. The mean age of onset in the progeny was 12.61 years compared to 41.22 years in the parent generation, (p < 0.001).Mean severity in the younger generation was slightly higher than that of the parent generation. When corrected for the age difference, the trend for a worse phenotype in the younger generation became statistically significant (p < 0.02,Wilcoxon signed rank test). Conclusions Our findings suggest that in a subgroup of CMT1A patients there is an increase in clinical severity over generations. The mechanism responsible for this observation remains unknown. Our findings should be validated on a larger cohort of CMT1A families.
- 30 April 2008
- Published by Springer Nature in Journal of Neurology
- Vol. 255 (6) , 813-819
Increased severity over generations of Charcot-Marie-Tooth disease type 1A
Background Charcot-Marie-Tooth type 1A (CMT1A) is an autosomal dominant polyneuropathy due to a 1.5 Mb tandem duplication in chromosome 17p11.2, containing the PMP22 gene. This mutation is not modified during inheritance. Objectives We set forth to test the hypothesis that in a subgroup of CMT1A patients there is clinical anticipation, namely an increase in disease severity over generations. Methods Thirty-nine CMT1A mutation-positive patients in 16 families and 23 parent-offspring pairs were evaluated. This included 14 families with 2 generations and 2 families with 3 generations. Age of presentation was assessed by interviewing the patients and clinical severity was measured using the CMT neuropathy score (CMTNS). Results In 21/23 parent-child pairs and 14/16 families, there was an earlier age of presentation in children of genetically affected parents. The mean age of onset in the progeny was 12.61 years compared to 41.22 years in the parent generation, (p < 0.001).Mean severity in the younger generation was slightly higher than that of the parent generation. When corrected for the age difference, the trend for a worse phenotype in the younger generation became statistically significant (p < 0.02,Wilcoxon signed rank test). Conclusions Our findings suggest that in a subgroup of CMT1A patients there is an increase in clinical severity over generations. The mechanism responsible for this observation remains unknown. Our findings should be validated on a larger cohort of CMT1A families.
- Top Cited Papers
- 1 November 2007
- Published by Elsevier in The Lancet Neurology
- Vol. 6 (11) , 1015-1028
The neurotropic herpes viruses: herpes simplex and varicella-zoster
- 1 November 2007
- Published by Elsevier in The Lancet Neurology
- Vol. 6 (11) , 1015-1028
Top Cited PapersThe neurotropic herpes viruses: herpes simplex and varicella-zoster
- Open Access
- 11 October 2007
- Published by S. Karger AG in European Neurology
- Vol. 59 (1-2) , 88-90
‘Hyperacute’ Guillain-Barré Syndrome
- 11 October 2007
- Published by S. Karger AG in European Neurology
- Vol. 59 (1-2) , 88-90
Open Access‘Hyperacute’ Guillain-Barré Syndrome
- 29 May 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (6) , e4
PANDAS in siblings: a common risk?
- 29 May 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (6) , e4
PANDAS in siblings: a common risk?
- 1 October 2006
- Published by Microbiology Society in Journal of General Virology
- Vol. 87 (10) , 2827-2837
Neurotropism of herpes simplex virus type 1 in brain organ cultures
The mechanism of herpes simplex virus type 1 (HSV-1) penetration into the brain and its predilection to infect certain neuronal regions is unknown. In order to study HSV-1 neurotropism, an ex vivo system of mice organotypic brain slices was established and the tissue was infected with HSV-1 vectors. Neonate tissues showed restricted infection confined to leptomeningeal, periventricular and cortical brain regions. The hippocampus was the primary parenchymatous structure that was also infected. Infection was localized to early progenitor and ependymal cells. Increasing viral inoculum increased the intensity and enlarged the infected territory, but the distinctive pattern of infection was maintained and differed from that observed with adenovirus and Vaccinia virus. Neonate brain tissues were much more permissive for HSV-1 infection than adult mouse brain tissues. Taken together, these results indicate a complex interaction of HSV-1 with different brain-cell types and provide a useful vehicle to elucidate the mechanisms of viral neurotropism.
- 1 October 2006
- Published by Microbiology Society in Journal of General Virology
- Vol. 87 (10) , 2827-2837
Neurotropism of herpes simplex virus type 1 in brain organ cultures
The mechanism of herpes simplex virus type 1 (HSV-1) penetration into the brain and its predilection to infect certain neuronal regions is unknown. In order to study HSV-1 neurotropism, an ex vivo system of mice organotypic brain slices was established and the tissue was infected with HSV-1 vectors. Neonate tissues showed restricted infection confined to leptomeningeal, periventricular and cortical brain regions. The hippocampus was the primary parenchymatous structure that was also infected. Infection was localized to early progenitor and ependymal cells. Increasing viral inoculum increased the intensity and enlarged the infected territory, but the distinctive pattern of infection was maintained and differed from that observed with adenovirus and Vaccinia virus. Neonate brain tissues were much more permissive for HSV-1 infection than adult mouse brain tissues. Taken together, these results indicate a complex interaction of HSV-1 with different brain-cell types and provide a useful vehicle to elucidate the mechanisms of viral neurotropism.
- 1 November 2005
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 1 (1) , 18-19
Can vaccinating older adults against varicella zoster virus prevent herpes zoster and postherpetic neuralgia?
- 1 November 2005
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 1 (1) , 18-19
Can vaccinating older adults against varicella zoster virus prevent herpes zoster and postherpetic neuralgia?
- Open Access
- 24 March 2005
- Published by Wiley in European Journal of Neurology
- Vol. 12 (5) , 331-343
Viral encephalitis: a review of diagnostic methods and guidelines for management
Viral encephalitis is a medical emergency. The spectrum of brain involvement and the prognosis are dependent mainly on the specific pathogen and the immunological state of the host. Although specific therapy is limited to only several viral agents, correct immediate diagnosis and introduction of symptomatic and specific therapy has a dramatic influence upon survival and reduces the extent of permanent brain injury in survivors. We searched MEDLINE (National Library of Medicine) for relevant literature from 1966 to May 2004. Review articles and book chapters were also included. Recommendations are based on this literature based on our judgment of the relevance of the references to the subject. Recommendations were reached by consensus. Where there was lack of evidence but consensus was clear we have stated our opinion as good practice points. Diagnosis should be based on medical history, examination followed by analysis of cerebrospinal fluid for protein and glucose contents, cellular analysis and identification of the pathogen by polymerase chain reaction (PCR) amplification (recommendation level A) and serology (recommendation level B). Neuroimaging, preferably by magnetic resonance imaging, is an essential aspect of evaluation (recommendation level B). Lumbar puncture can follow neuroimaging when immediately available, but if this cannot be obtained at the shortest span of time it should be delayed only in the presence of strict contraindications. Brain biopsy should be reserved only for unusual and diagnostically difficult cases. All encephalitis cases must be hospitalized with an access to intensive care units. Supportive therapy is an important basis of management. Specific, evidence‐based, anti‐viral therapy, acyclovir, is available for herpes encephalitis (recommendation level A). Acyclovir might also be effective for varicella‐zoster virus encephalitis, gancyclovir and foscarnet for cytomegalovirus encephalitis and pleconaril for enterovirus encephalitis (IV class of evidence). Corticosteroids as an adjunct treatment for acute viral encephalitis are not generally considered to be effective and their use is controversial. Surgical decompression is indicated for impending uncal herniation or increased intracranial pressure refractory to medical management.
- 24 March 2005
- Published by Wiley in European Journal of Neurology
- Vol. 12 (5) , 331-343
Open AccessViral encephalitis: a review of diagnostic methods and guidelines for management
Viral encephalitis is a medical emergency. The spectrum of brain involvement and the prognosis are dependent mainly on the specific pathogen and the immunological state of the host. Although specific therapy is limited to only several viral agents, correct immediate diagnosis and introduction of symptomatic and specific therapy has a dramatic influence upon survival and reduces the extent of permanent brain injury in survivors. We searched MEDLINE (National Library of Medicine) for relevant literature from 1966 to May 2004. Review articles and book chapters were also included. Recommendations are based on this literature based on our judgment of the relevance of the references to the subject. Recommendations were reached by consensus. Where there was lack of evidence but consensus was clear we have stated our opinion as good practice points. Diagnosis should be based on medical history, examination followed by analysis of cerebrospinal fluid for protein and glucose contents, cellular analysis and identification of the pathogen by polymerase chain reaction (PCR) amplification (recommendation level A) and serology (recommendation level B). Neuroimaging, preferably by magnetic resonance imaging, is an essential aspect of evaluation (recommendation level B). Lumbar puncture can follow neuroimaging when immediately available, but if this cannot be obtained at the shortest span of time it should be delayed only in the presence of strict contraindications. Brain biopsy should be reserved only for unusual and diagnostically difficult cases. All encephalitis cases must be hospitalized with an access to intensive care units. Supportive therapy is an important basis of management. Specific, evidence‐based, anti‐viral therapy, acyclovir, is available for herpes encephalitis (recommendation level A). Acyclovir might also be effective for varicella‐zoster virus encephalitis, gancyclovir and foscarnet for cytomegalovirus encephalitis and pleconaril for enterovirus encephalitis (IV class of evidence). Corticosteroids as an adjunct treatment for acute viral encephalitis are not generally considered to be effective and their use is controversial. Surgical decompression is indicated for impending uncal herniation or increased intracranial pressure refractory to medical management.
- 1 December 2003
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (23) , 12421-12429
Transgenic Mouse with the Herpes Simplex Virus Type 1 Latency-Associated Gene: Expression and Function of the Transgene
During herpes simplex virus type 1 (HSV-1) latent infection in human peripheral sensory ganglia, the major viral gene transcribed is the latency-associated transcript (LAT) gene. In order to facilitate the study of this gene, we generated a transgenic mouse that contains the DNA fragment that transcribes the LAT RNAs (2.0 kb and its 1.5-kb spliced transcript) under control of the cytomegalovirus promoter. The tissue distribution of these transcripts and their effects upon HSV-1 replication, latency, and reactivation in the transgenic-mouse model were examined. Different steady-state amounts of both transcripts were found in various tissues. While the highest levels of the 2.0-kb RNA were detected in heart and skeletal muscle, the 1.5-kb transcript was found at elevated levels in the brain and at much higher levels in the trigeminal ganglia (TG). Replication of both the wild-type and a LAT-negative mutant virus was suppressed in primary embryonic fibroblasts obtained from LAT-expressing transgenic mice compared to that in cells obtained from normal mice. HSV-1 DNA amounts in latently infected TG of transgenic mice were similar to those in normal mice. Reactivation of latent HSV-1 LAT-negative mutants by explant cocultivation of TG from transgenic mice was more efficient than reactivation from normal-mouse TG. Considering our present and previous results, we propose that the significantly higher steady-state level of the 1.5-kb RNA in the TG may link this transcript to latency functions and that by inhibition of virus replication, the LAT gene may protect ganglion cells and thereby increase the probability of reactivation.
- 1 December 2003
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (23) , 12421-12429
Transgenic Mouse with the Herpes Simplex Virus Type 1 Latency-Associated Gene: Expression and Function of the Transgene
During herpes simplex virus type 1 (HSV-1) latent infection in human peripheral sensory ganglia, the major viral gene transcribed is the latency-associated transcript (LAT) gene. In order to facilitate the study of this gene, we generated a transgenic mouse that contains the DNA fragment that transcribes the LAT RNAs (2.0 kb and its 1.5-kb spliced transcript) under control of the cytomegalovirus promoter. The tissue distribution of these transcripts and their effects upon HSV-1 replication, latency, and reactivation in the transgenic-mouse model were examined. Different steady-state amounts of both transcripts were found in various tissues. While the highest levels of the 2.0-kb RNA were detected in heart and skeletal muscle, the 1.5-kb transcript was found at elevated levels in the brain and at much higher levels in the trigeminal ganglia (TG). Replication of both the wild-type and a LAT-negative mutant virus was suppressed in primary embryonic fibroblasts obtained from LAT-expressing transgenic mice compared to that in cells obtained from normal mice. HSV-1 DNA amounts in latently infected TG of transgenic mice were similar to those in normal mice. Reactivation of latent HSV-1 LAT-negative mutants by explant cocultivation of TG from transgenic mice was more efficient than reactivation from normal-mouse TG. Considering our present and previous results, we propose that the significantly higher steady-state level of the 1.5-kb RNA in the TG may link this transcript to latency functions and that by inhibition of virus replication, the LAT gene may protect ganglion cells and thereby increase the probability of reactivation.
- 1 April 2002
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (4) , 647-648
Neurological Deficits in Patients With Celiac Disease
Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten in genetically susceptible individuals. Developments in the understanding
- 1 April 2002
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (4) , 647-648
Neurological Deficits in Patients With Celiac Disease
Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten in genetically susceptible individuals. Developments in the understanding
- Open Access
- 1 July 2001
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 8 (4) , 850-851
Spinal Cord Involvement in Uncomplicated Herpes Zoster
We prospectively evaluated herpes zoster patients during the acute phase of the disease for central nervous system involvement. Of 24 patients with spinal zoster, 13 (54%) had spinal cord abnormality, which was asymptomatic in 12 of the 13. Age but not lack of acyclovir treatment was associated with such involvement. In all but 2, neurological involvement resolved within 6 months. Although the mechanism responsible for the neurological abnormalities is unknown, findings may support the hypothesis that zoster is associated with spread of viral infection into the spinal cord and therefore support the possibility that zoster is due to active viral replication in the ganglion.
- 1 July 2001
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 8 (4) , 850-851
Open AccessSpinal Cord Involvement in Uncomplicated Herpes Zoster
We prospectively evaluated herpes zoster patients during the acute phase of the disease for central nervous system involvement. Of 24 patients with spinal zoster, 13 (54%) had spinal cord abnormality, which was asymptomatic in 12 of the 13. Age but not lack of acyclovir treatment was associated with such involvement. In all but 2, neurological involvement resolved within 6 months. Although the mechanism responsible for the neurological abnormalities is unknown, findings may support the hypothesis that zoster is associated with spread of viral infection into the spinal cord and therefore support the possibility that zoster is due to active viral replication in the ganglion.